Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Omega Diagnostics Group Plc (LON:ODX) has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious
Sinclair Pharma Plc (LON:SPH) has evolved into a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics products. These products target unmet clinical needs for
PPHE Hotel Group Ltd (LON:PPH) trading update confirmed that trading was in line with expectations and that the new hotels are due to open in Q4 as planned. This is
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Planning Permission
Omega Diagnostics Group plc (LON:ODX) has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious
Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort® and Chronocort® – in Phase
Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
